118 related articles for article (PubMed ID: 27460209)
21. Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
Schirok H; Kast R; Figueroa-Pérez S; Bennabi S; Gnoth MJ; Feurer A; Heckroth H; Thutewohl M; Paulsen H; Knorr A; Hütter J; Lobell M; Münter K; Geiss V; Ehmke H; Lang D; Radtke M; Mittendorf J; Stasch JP
ChemMedChem; 2008 Dec; 3(12):1893-904. PubMed ID: 18973168
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and SAR studies of indole-based MK2 inhibitors.
Xiong Z; Gao DA; Cogan DA; Goldberg DR; Hao MH; Moss N; Pack E; Pargellis C; Skow D; Trieselmann T; Werneburg B; White A
Bioorg Med Chem Lett; 2008 Mar; 18(6):1994-9. PubMed ID: 18291646
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
Krishnaiah M; Jin CH; Sheen YY; Kim DK
Bioorg Med Chem Lett; 2015 Nov; 25(22):5228-31. PubMed ID: 26483198
[TBL] [Abstract][Full Text] [Related]
24. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
[TBL] [Abstract][Full Text] [Related]
25. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK
Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5).
Li X; Wang L; Long L; Xiao J; Hu Y; Li S
Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940
[TBL] [Abstract][Full Text] [Related]
28. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors.
Moriarty KJ; Koblish HK; Garrabrant T; Maisuria J; Khalil E; Ali F; Petrounia IP; Crysler CS; Maroney AC; Johnson DL; Galemmo RA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5778-83. PubMed ID: 16949284
[TBL] [Abstract][Full Text] [Related]
29. Induction of heart valve lesions by small-molecule ALK5 inhibitors.
Anderton MJ; Mellor HR; Bell A; Sadler C; Pass M; Powell S; Steele SJ; Roberts RR; Heier A
Toxicol Pathol; 2011 Oct; 39(6):916-24. PubMed ID: 21859884
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and activity of a potent, selective series of N-aryl pyridinone inhibitors of p38 kinase.
Selness SR; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R; Devraj RV; Messing D; Schindler JF; Hirsch J; Saabye M; Bonar S; Webb E; Anderson G; Monahan JB
Bioorg Med Chem Lett; 2011 Jul; 21(13):4059-65. PubMed ID: 21640588
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM
J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047
[TBL] [Abstract][Full Text] [Related]
32. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
Park CY; Son JY; Jin CH; Nam JS; Kim DK; Sheen YY
Eur J Cancer; 2011 Nov; 47(17):2642-53. PubMed ID: 21852112
[TBL] [Abstract][Full Text] [Related]
33. 3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.
Soth M; Abbot S; Abubakari A; Arora N; Arzeno H; Billedeau R; Dewdney N; Durkin K; Frauchiger S; Ghate M; Goldstein DM; Hill RJ; Kuglstatter A; Li F; Loe B; McCaleb K; McIntosh J; Papp E; Park J; Stahl M; Sung ML; Suttman R; Swinney DC; Weller P; Wong B; Zecic H; Gabriel T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3452-6. PubMed ID: 21515047
[TBL] [Abstract][Full Text] [Related]
34. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
DaCosta Byfield S; Major C; Laping NJ; Roberts AB
Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253
[TBL] [Abstract][Full Text] [Related]
35. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Park HJ; Park SJ; Sheen YY; Kim DK
Bioorg Med Chem; 2014 May; 22(9):2724-32. PubMed ID: 24704197
[TBL] [Abstract][Full Text] [Related]
36. Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity.
Gourdain S; Dairou J; Denhez C; Bui LC; Rodrigues-Lima F; Janel N; Delabar JM; Cariou K; Dodd RH
J Med Chem; 2013 Dec; 56(23):9569-85. PubMed ID: 24188002
[TBL] [Abstract][Full Text] [Related]
37. Identification of ALK5 inhibitor via structure-based virtual screening and ADMET prediction.
Lin A; Cai Z; Hu G; Li Q
J Recept Signal Transduct Res; 2015; 35(6):559-64. PubMed ID: 26042458
[TBL] [Abstract][Full Text] [Related]
38. Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.
Li HY; Wang Y; Yan L; Campbell RM; Anderson BD; Wagner JR; Yingling JM
Bioorg Med Chem Lett; 2004 Jul; 14(13):3585-8. PubMed ID: 15177480
[TBL] [Abstract][Full Text] [Related]
39. Discovery of novel 7-azaindoles as PDK1 inhibitors.
Wucherer-Plietker M; Merkul E; Müller TJJ; Esdar C; Knöchel T; Heinrich T; Buchstaller HP; Greiner H; Dorsch D; Finsinger D; Calderini M; Bruge D; Grädler U
Bioorg Med Chem Lett; 2016 Jul; 26(13):3073-3080. PubMed ID: 27217002
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of 5-(pyridin-2-yl)thiazoles as transforming growth factor-beta type1 receptor kinase inhibitors.
Kim DK; Choi JH; An YJ; Lee HS
Bioorg Med Chem Lett; 2008 Mar; 18(6):2122-7. PubMed ID: 18262787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
